Table 2.

Primary Efficacy End Point: Proportion of patients developing new gastro duodenal events (Non-responders).

Visit	Parameter	Test (N = 154)	Comparator (N = 76)	Difference in % of Non-responders & P Value
Visit 5 (Week 12)	Proportion of Non-Responders	15 (9.7)	15 (19.7)	10.0 (0.21; 21.32) & 0.0285
	Proportion of Responders	134 (87.0)	57 (75.0)
Visit 7 (Week 24)	Proportion of Non Responders	17 (11.0)	17 (22.4)	11.33 (0.73; 21.93) & 0.0228
	Proportion of Responders	137 (89.0)	59 (77.6)

Test: Fixed dose combination of Aspirin 150 mg and Pantoprazole 20 mg.

Comparator: Aspirin 150 mg.

Data presented as n (%).

P Value based on Chi-square Test.